摘要
目的分析晚期肺癌患者接受阿帕替尼联合化疗治疗的效果及预后。方法选取2019年1月至2020年12月我院收治的晚期肺癌患者54例作为研究对象,根据不同治疗方式进行分组,每组27例,对照组行化疗治疗,试验组行阿帕替尼联合化疗治疗。对比临床疗效。结果试验组临床疗效、胃肠道反应发生率、脱发发生率、骨髓抑制发生率、CEA水平、CA125水平、CYFRA21-1水平均优于对照组(P<0.05)。结论阿帕替尼联合化疗治疗可降低癌细胞转移率,降低患者的不良反应,提高患者治疗效果,延长患者的生存周期。
Objective To analyze the effect and prognosis of patients with advanced lung cancer treated with apatinib combined with chemotherapy.Method A total of 54 cases of advanced lung cancer patients admitted to our hospital from January 2019 to December 2020 were selected as the research objects,and they were divided into groups according to different treatment methods,27 cases in each group,the control group received chemotherapy treatment,and the experimental group received apatinib combined with chemotherapy treatment.Compare the clinical efficacy.Result The clinical efficacy,incidence of gastrointestinal reactions,incidence of hair loss,incidence of bone marrow suppression,CEA level,CA125 level,and CYFRA21-1 level of the experimental group were better than those of the control group(P<0.05).Conclusion Apatinib combined with chemotherapy can reduce the metastasis rate of cancer cells,reduce the adverse reactions of patients,improve the treatment effect of patients and prolong the life cycle of patients,which is worthy of application and promotion.
作者
邢永达
XING Yongda(The First People's Hospital of Jinzhou District in Dalian City,Dalian 116100,China)
出处
《中国医药指南》
2021年第7期10-11,共2页
Guide of China Medicine
关键词
晚期肺癌
靶向治疗
化疗
临床疗效
Advanced lung cancer
Targeted therapy
Chemotherapy
Clinical efficacy
